{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:50:15Z","timestamp":1793731815069,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:03:36Z","timestamp":1745852616000},"page":"1203-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct Treatment of All Visible Tumour in Synchronous Oligometastatic Prostate Cancer: Total Eradication of Tumour or the Full Monty Treatment"],"prefix":"10.1016","volume":"8","author":[{"given":"Alexander","family":"Giesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"De Preter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.011_b0005","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: prostate cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.euo.2025.04.011_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.011_b0015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.011_b0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.011_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.04.011_b0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.adro.2020.06.018","article-title":"Clinical outcomes of combined prostate- and metastasis-directed radiation therapy for the treatment of de novo oligometastatic prostate cancer","volume":"5","author":"Imber","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euo.2025.04.011_b0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-020-01385-7","article-title":"Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer","volume":"37","author":"Reyes","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.euo.2025.04.011_b0040","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190353","article-title":"Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases","volume":"93","author":"Deantoni","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euo.2025.04.011_b0045","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00345-023-04460-6","article-title":"Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer","volume":"41","author":"Pellegrino","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.04.011_b0050","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European study","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.011_b0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.euo.2025.04.011_b0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.011_b0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:27:50Z","timestamp":1758079670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001051"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.011","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct Treatment of All Visible Tumour in Synchronous Oligometastatic Prostate Cancer: Total Eradication of Tumour or the Full Monty Treatment","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}